- Monoclonal Antibodies (mAb)
- Fusion Proteins
- Immunosuppressants
- Polyclonal Antibody (pAb)
- Others
Immunology Market size was valued at USD 93,486.5 million in 2022 and is expected to grow at a significant CAGR of 8.5% from 2023 to 2029. The global market provides a detailed overview of The Immunology Market and and can be segmented by Drug Class, Indication, Distribution Channel. By drug class, the Immunology market has been segmented into Monoclonal Antibodies (mAb), Fusion Proteins, Immunosuppressants, Polyclonal antibodies (pAb), and Others. The monoclonal antibodies segment is likely to be the largest and fastest-growing segment in terms of type. Based on Indication, the immunology market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Lupus, Ankylosing Spondylitis, Inflammatory Bowel Disease, and Others. Among these, the Rheumatoid Arthritis segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on Distribution Channel, the immunology market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies segment accounts for the largest share in 2021. Retail Pharmacies is the second-largest share during the forecast period 2021-2028 according to Precision Business Insights.
Immunology Market Key Developments:
- In May 2020, AbbVie, Inc. announced the acquisition of Allergan Plc with an aim to expand its presence and strengthen its position in the pharmaceuticals sector across the globe.
Immunology Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
8.5%
Largest Market
Asia Pacific
Fastest Growing Market
North America
Immunology Market Dynamics
The increase in the prevalence rate of the different types of cancer and rheumatoid arthritis, rising government initiatives, and increasing funding from the various government and non-government organizations is driving the immunology market.
Key Features of the Reports
- The immunology market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Immunology Market Segmentation
By Drug Class
By Indication
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Lupus
- Ankylosing Spondylitis
- Inflammatory Bowel Disease
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Frequently Asked Questions
The immunology market is projected to expand at a CAGR of 8.5% during the forecast period.
Amgen Inc., Novartis AG, Janssen Global Services, LLC, Astellas Pharma inc., UCB SA, Eli Lilly and Company
North America is the fastest-growing region for immunology market
| 1. Executive Summary |
| 2. Global Immunology Market Introduction |
| 2.1. Global Immunology Market - Taxonomy |
| 2.2. Global Immunology Market -Definitions |
| 2.2.1. By Drug Class |
| 2.2.2. By Indication |
| 2.2.3. By Distribution Channel |
| 2.2.4. By Region |
| 3. Global Immunology Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Immunology Market Dynamic Factors - Impact Analysis |
| 3.6. Global Immunology Market - Competition Landscape |
| 4. Global Immunology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Immunology Market, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Monoclonal Antibodies (mAb) |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Fusion Proteins |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Immunosuppressants |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Polyclonal Antibody (pAb) |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Immunology Market, By Indication, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Rheumatoid Arthritis |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Psoriatic Arthritis |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Plaque Psoriasis |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Lupus |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Ankylosing Spondylitis |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Inflammatory Bowel Disease |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Others |
| 6.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7. Global Immunology Market, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Hospital Pharmacies |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail Pharmacies |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online Pharmacies |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Immunology Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Immunology Market - Opportunity Analysis Index, By Drug Class, By Indication, By Distribution Channel, and Region, 2023 - 2029 |
| 9. North America Immunology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Monoclonal Antibodies (mAb) |
| 9.1.2. Fusion Proteins |
| 9.1.3. Immunosuppressants |
| 9.1.4. Polyclonal Antibody (pAb) |
| 9.1.5. Others |
| 9.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Rheumatoid Arthritis |
| 9.2.2. Psoriatic Arthritis |
| 9.2.3. Plaque Psoriasis |
| 9.2.4. Lupus |
| 9.2.5. Ankylosing Spondylitis |
| 9.2.6. Inflammatory Bowel Disease |
| 9.2.7. Others |
| 9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Hospital Pharmacies |
| 9.3.2. Retail Pharmacies |
| 9.3.3. Online Pharmacies |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Immunology Market - Opportunity Analysis Index, By Drug Class, By Indication, By Distribution Channel, and Country, 2023 - 2029 |
| 9.6. North America Immunology Market Dynamics - Trends |
| 10. Europe Immunology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Monoclonal Antibodies (mAb) |
| 10.1.2. Fusion Proteins |
| 10.1.3. Immunosuppressants |
| 10.1.4. Polyclonal Antibody (pAb) |
| 10.1.5. Others |
| 10.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Rheumatoid Arthritis |
| 10.2.2. Psoriatic Arthritis |
| 10.2.3. Plaque Psoriasis |
| 10.2.4. Lupus |
| 10.2.5. Ankylosing Spondylitis |
| 10.2.6. Inflammatory Bowel Disease |
| 10.2.7. Others |
| 10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Hospital Pharmacies |
| 10.3.2. Retail Pharmacies |
| 10.3.3. Online Pharmacies |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Rest of Europe |
| 10.5. Europe Immunology Market - Opportunity Analysis Index, By Drug Class, By Indication, By Distribution Channel, and Country, 2023 - 2029 |
| 10.6. Europe Immunology Market Dynamics - Trends |
| 11. Asia-Pacific Immunology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Monoclonal Antibodies (mAb) |
| 11.1.2. Fusion Proteins |
| 11.1.3. Immunosuppressants |
| 11.1.4. Polyclonal Antibody (pAb) |
| 11.1.5. Others |
| 11.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Rheumatoid Arthritis |
| 11.2.2. Psoriatic Arthritis |
| 11.2.3. Plaque Psoriasis |
| 11.2.4. Lupus |
| 11.2.5. Ankylosing Spondylitis |
| 11.2.6. Inflammatory Bowel Disease |
| 11.2.7. Others |
| 11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Hospital Pharmacies |
| 11.3.2. Retail Pharmacies |
| 11.3.3. Online Pharmacies |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. China |
| 11.4.2. India |
| 11.4.3. Japan |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Immunology Market - Opportunity Analysis Index, By Drug Class, By Indication, By Distribution Channel, and Country, 2023 - 2029 |
| 11.6. Asia-Pacific Immunology Market Dynamics - Trends |
| 12. Latin America Immunology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Monoclonal Antibodies (mAb) |
| 12.1.2. Fusion Proteins |
| 12.1.3. Immunosuppressants |
| 12.1.4. Polyclonal Antibody (pAb) |
| 12.1.5. Others |
| 12.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Rheumatoid Arthritis |
| 12.2.2. Psoriatic Arthritis |
| 12.2.3. Plaque Psoriasis |
| 12.2.4. Lupus |
| 12.2.5. Ankylosing Spondylitis |
| 12.2.6. Inflammatory Bowel Disease |
| 12.2.7. Others |
| 12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Hospital Pharmacies |
| 12.3.2. Retail Pharmacies |
| 12.3.3. Online Pharmacies |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Immunology Market - Opportunity Analysis Index, By Drug Class, By Indication, By Distribution Channel, and Country, 2023 - 2029 |
| 12.6. Latin America Immunology Market Dynamics - Trends |
| 13. Middle East and Africa Immunology Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 13.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Monoclonal Antibodies (mAb) |
| 13.1.2. Fusion Proteins |
| 13.1.3. Immunosuppressants |
| 13.1.4. Polyclonal Antibody (pAb) |
| 13.1.5. Others |
| 13.2. Indication Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Rheumatoid Arthritis |
| 13.2.2. Psoriatic Arthritis |
| 13.2.3. Plaque Psoriasis |
| 13.2.4. Lupus |
| 13.2.5. Ankylosing Spondylitis |
| 13.2.6. Inflammatory Bowel Disease |
| 13.2.7. Others |
| 13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Hospital Pharmacies |
| 13.3.2. Retail Pharmacies |
| 13.3.3. Online Pharmacies |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Immunology Market - Opportunity Analysis Index, By Drug Class, By Indication, By Distribution Channel, and Country, 2023 - 2029 |
| 13.6. MEA Immunology Market Dynamics - Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Pfizer, Inc. |
| 14.2.2. F. Hoffmann-La Roche Ltd. |
| 14.2.3. AbbVie, Inc. |
| 14.2.4. Bristol-Mayers Squibb Company |
| 14.2.5. Merck Sharp & Dohme Corp. |
| 14.2.6. Novartis AG |
| 14.2.7. Janssen Global Services, LLC |
| 14.2.8. Amgen Inc. |
| 14.2.9. Astellas Pharma inc. |
| 14.2.10. UCB SA |
| 14.2.11. Eli Lilly and Company |
| 14.2.12. Allergan plc. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- AbbVie, Inc.
- Bristol-Mayers Squibb Company
- Pfizer, Inc.
- Hoffmann-La Roche Ltd.
- Allergan plc.
- Merck Sharp & Dohme Corp.
- Novartis AG
- Janssen Global Services, LLC
- Amgen Inc.
- Astellas Pharma inc.
- UCB SA
- Eli Lilly and Company